RBC Capital Maintains Sector Perform on Moderna, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains a Sector Perform rating on Moderna (NASDAQ:MRNA) but lowers the price target from $90 to $75.
September 13, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Moderna but reduced the price target from $90 to $75, indicating a less optimistic outlook.
The reduction in price target from $90 to $75 by RBC Capital suggests a less optimistic view on Moderna's stock performance. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations based on the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100